Actinogen Medical Limited (AU:ACW)
ASX:ACW
Want to see AU:ACW full AI Analyst Report?
ACW Stock Chart & Stats
AU$0.04
>-AU$0.01(-3.85%)
At close: 4:00 PM EST
AU$0.04
>-AU$0.01(-3.85%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.07
Previous CloseN/A
Volume244.11K
Average Volume (3M)6.03M
Market Cap
AU$135.34M
Enterprise ValueAU$130.21M
Total Cash (Recent Filing)AU$6.53M
Total Debt (Recent Filing)AU$366.31K
Price to Earnings (P/E)―
Beta-0.29
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding3,657,944,300
10 Day Avg. Volume4,755,726
30 Day Avg. Volume6,028,147
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)3.74
Price to Sales (P/S)12.48
P/FCF Ratio-9.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.08Price Target Upside100.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$5.50M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Healthy EquityA low debt-to-equity position and relatively healthy equity ratio reduce financing risk and provide structural flexibility. Over the next 2–6 months this limits default risk, preserves optionality for non-dilutive financing or partnerships, and supports continuing R&D spend without heavy interest burdens.
High Gross Profit MarginA reported 100% gross margin reflects minimal direct cost of goods sold in current operations. If commercialized, this structural margin profile would allow scalable profitability leverage on future revenues and ease pressure on EBITDA conversion, benefiting long-term product economics once revenue begins.
Focused Lead Candidate And StrategyA concentrated pipeline with a clearly defined lead asset (Xanamem) focuses resources and simplifies clinical and partnership strategy. Structurally, this enhances clarity for potential licensing, collaboration, or targeted fundraising, making business development and value realization paths more actionable over months.
Bears Say
Sharp Revenue DeclineA nearly 40% revenue decline signals weakening recurring receipts or grants and reduces internal funding capacity. For a clinical-stage biotech this worsens runway metrics, increases reliance on external capital, and structurally raises dilution and execution risk over the coming quarters absent new funding or material financing events.
Negative Operating & Free Cash FlowPersistent negative operating and free cash flow, with declining FCF, indicate ongoing cash burn that must be financed externally. Structurally this constrains sustained trial investment, elevates the probability of dilutive equity raises or less favorable partnerships, and pressures strategic flexibility over 2–6 months.
Deep, Persistent LossesConsistently negative profitability metrics and a negative ROE show the company is not generating shareholder returns from operations. Over the medium term this erodes equity value if left unchecked, necessitates repeated external financing for development, and makes sustaining an independent commercial model more challenging.
Actinogen Medical News
ACW FAQ
What was Actinogen Medical Limited’s price range in the past 12 months?
Actinogen Medical Limited lowest share price was AU$0.02 and its highest was AU$0.07 in the past 12 months.
What is Actinogen Medical Limited’s market cap?
Actinogen Medical Limited’s market cap is AU$135.34M.
When is Actinogen Medical Limited’s upcoming earnings report date?
Actinogen Medical Limited’s upcoming earnings report date is Aug 31, 2026 which is in 85 days.
How were Actinogen Medical Limited’s earnings last quarter?
Actinogen Medical Limited released its earnings results on Feb 25, 2026. The company reported -AU$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.004.
Is Actinogen Medical Limited overvalued?
According to Wall Street analysts Actinogen Medical Limited’s price is currently Undervalued.
Does Actinogen Medical Limited pay dividends?
Actinogen Medical Limited does not currently pay dividends.
What is Actinogen Medical Limited’s EPS estimate?
Actinogen Medical Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Actinogen Medical Limited have?
Actinogen Medical Limited has 3,657,944,300 shares outstanding.
What happened to Actinogen Medical Limited’s price movement after its last earnings report?
Actinogen Medical Limited reported an EPS of -AU$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Actinogen Medical Limited?
Currently, no hedge funds are holding shares in AU:ACW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Actinogen Medical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.08 (100.00% Upside)
AU$0.08 (100.00% Upside)
Blogger Sentiment
Bullish
AU:ACW Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$667.0K over
the Last 3 Months
the Last 3 Months
Fundamentals
Return on Equity
-134.14%
Trailing 12-Months
Asset Growth
-55.10%
Trailing 12-Months
Company Description
Actinogen Medical Limited
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It is developing Xanamem, an inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials that achieves target engagement in the central nervous system, Alzheimer's disease, depression with cognitive impairment, and anxiety, sleep, and behavioral problems in fragile X syndrome. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.
ACW Stock 12 Month Forecast
Average Price Target
AU$0.08
▲(100.00% Upside)
Technical Analysis
Tryptamine Therapeutics
―
Neuren Pharmaceuticals Limited
―
Alterity Therapeutics
―
Zelira Therapeutics
―
Neuroscientific Biopharmaceuticals Ltd.
―
Options Prices
Currently, No data available
---